BANK VONTOBEL/PUT/VERTEX PHARMACEUTICALS/400/0.1/20.12.24

BANK VONTOBEL/PUT/VERTEX PHARMACEUTICALS/400/0.1/20.12.24 Share Price

DE000VD3R7S9

Market Closed - Boerse Frankfurt Warrants 18:48:05 27/06/2024 BST
0.85 ^EUR	-5.56%

Current month	-46.20%
1 month	-30.89%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart VERTEX PHARMACEUTICALS INCORPORATED

Chart BANK VONTOBEL/PUT/VERTEX PHARMACEUTICALS/400/0.1/20.12.24

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

Redburn Atlantic Initiates Vertex Pharmaceuticals at Buy With $545 Price Target	06-27	MT
Piper Sandler Adjusts Price Target on Vertex Pharmaceuticals to $500 From $456, Maintains Overweight Rating	06-25	MT
Wells Fargo Adjusts Price Target on Vertex Pharmaceuticals to $555 From $540	06-24	MT
Vertex Pharmaceuticals Discloses 'Positive' Data From Phase 1/2 Trial of VX-880 to Treat Type 1 Diabetes	06-21	MT

More news

Quotes 5-day view

Date	Price	Change
27/06/24	0.85	-5.56%
26/06/24	0.9	-2.17%
25/06/24	0.92	+1.10%
24/06/24	0.91	-12.50%
21/06/24	1.04	+7.22%

Real-time Boerse Frankfurt Warrants

Last update June 27, 2024 at 06:48 pm

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	PUT
Underlying	VERTEX PHARMACEUTICALS INCORPORATED
Issuer	Vontobel
WKN	VD3R7S
ISIN	DE000VD3R7S9
Date issued	09/04/2024
Strike	400 $
Maturity	20/12/2024 (176 Days)
Parity	10 : 1
Emission price	2.76 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	3.54 €
Lowest since issue	0.79 €
Spread	0.04 €
Spread %	4.17%

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

More about the company